Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per Share

Brokerages predict that Neurocrine Biosciences (NASDAQ:NBIX) will post ($0.32) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.46). Neurocrine Biosciences posted earnings of ($0.90) per share during the same quarter last year, which would indicate a positive year over year growth rate of 64.4%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, May 8th.

On average, analysts expect that Neurocrine Biosciences will report full-year earnings of ($0.23) per share for the current financial year, with EPS estimates ranging from ($0.66) to $0.37. For the next year, analysts forecast that the company will post earnings of $1.83 per share, with EPS estimates ranging from $0.67 to $2.70. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Neurocrine Biosciences.

How to Become a New Pot Stock Millionaire

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The company had revenue of $94.52 million for the quarter, compared to analyst estimates of $94.00 million. During the same period in the previous year, the business earned ($0.51) EPS.

A number of research firms recently issued reports on NBIX. Jefferies Group raised their price objective on shares of Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a report on Friday, January 5th. JPMorgan Chase lifted their target price on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. Barclays reiterated an “overweight” rating and issued a $100.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, February 14th. Oppenheimer set a $110.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $110.00 target price (up previously from $95.00) on shares of Neurocrine Biosciences in a research note on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $95.23.

In other news, insider Haig P. Bozigian sold 1,625 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $79.12, for a total value of $128,570.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William H. Rastetter sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $855,000.00. Following the completion of the transaction, the director now owns 34,250 shares of the company’s stock, valued at $3,082,500. The disclosure for this sale can be found here. Insiders sold 367,136 shares of company stock valued at $30,001,192 in the last quarter. Corporate insiders own 4.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the period. Amalgamated Bank boosted its position in shares of Neurocrine Biosciences by 5.7% in the fourth quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock valued at $1,357,000 after acquiring an additional 947 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Neurocrine Biosciences by 25.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock valued at $458,000 after acquiring an additional 1,200 shares during the period. Crow Point Partners LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $145,000. Finally, American International Group Inc. bought a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $161,000.

NASDAQ NBIX traded down $0.56 during trading hours on Friday, reaching $75.33. 685,887 shares of the company were exchanged, compared to its average volume of 825,647. Neurocrine Biosciences has a 1 year low of $41.76 and a 1 year high of $92.98. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20. The company has a market capitalization of $6,821.15, a PE ratio of -46.50 and a beta of 0.29.

WARNING: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/04/15/neurocrine-biosciences-nbix-expected-to-announce-earnings-of-0-32-per-share.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply